Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group-Reference-Cited by-同舟云学术

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Published:2016-09 Issue:9 Volume:27 Page:1746-1753
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Modest D.P.,Ricard I.,Heinemann V.,Hegewisch-Becker S.,Schmiegel W.,Porschen R.,Stintzing S.,Graeven U.,Arnold D.,von Weikersthal L.F.,Giessen-Jung C.,Stahler A.,Schmoll H.J.,Jung A.,Kirchner T.,Tannapfel A.,Reinacher-Schick A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/9/1746/16698299/mdw261.pdf

Reference31 articles.

1. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer;Douillard;N Engl J Med,2013

2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

3. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer;Van Cutsem;J Clin Oncol,2015

4. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype;Bazan;Ann Oncol,2002

5. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study;Cremolini;Lancet Oncol,2015

Cited by 224 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations;Cancers;2024-09-12

2. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival;JAMA Oncology;2024-09-12

3. Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report;World Journal of Clinical Cases;2024-09-06

4. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;ESMO Open;2024-09

5. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer;Clinical Colorectal Cancer;2024-09